NCT02817217

The DDI Study of SP2086 and Valsartan

The Drug Interaction Study of SP2086 and Valsartan in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to investigate the potential PK interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy male volunteers.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	SP2086	SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
DRUG	Valsartan	SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.

Timeline

• Start date: 2016-03-01
• Primary completion: 2016-07-01
• First posted: 2016-06-29
• Last updated: 2016-06-29

Locations

1 site across 1 country: China